KRAS and neoplasm: The authors found that the genetic ablation of AIM2 in mutated KrasG12D LUAD mouse models significantly reduced tumor growth, and that AIM2 expression was required in both hematopoietic and non-hematopoietic cellular compartments for Kras G12D-driven LUAD establishment [100].